Table 1.

Baseline demographic, somatometric, clinical and laboratory data of the study population

ParameterControl SubjectsAll PatientsProgressorsNonprogressorsP
n:14n:96n:31 (32%)n:65 (68%)
Gender, M/F7/748/4815/1633/320.54
Age, yrs58 ± 1357 ± 1661 ± 1656 ± 170.03
BMI, kg/m226.9 ± 4.727.1 ± 526.2 ± 7.128.3 ± 6.50.45
BP, mmHg
    systolic128 ± 16130 ± 18130 ± 7130 ± 110.85
    diastolic75 ± 1077 ± 978 ± 976 ± 80.32
Diabetics, n, %21 (22%)8 (25%)13 (20%)0.10
eGFR, ml/min/1.73 m2111.6 ± 18.741.8 ± 19.134.3 ± 11.444.4 ± 13.60.02
Serum creatinine, mg/dl0.9 ± 0.32.83 ± 1.373.19 ± 1.482.66 ± 1.280.03
Albumin, g/dl4.02 ± 0.833.99 ± 0.644.11 ± 0.603.94 ± 0.650.56
Calcium, mg/dl9.39 ± 1.39.04 ± 0.909.03 ± 1.099.04 ± 0.630.79
Phosphate, mg/dl3.91 ± 0.924.26 ± 1.174.78 ± 1.264.15 ± 1.120.03
Ca × P product, mg2/dl232.7 ± 3.1538.9 ± 10.440.2 ± 11.637.4 ± 9.60.04
Hemoglobin, g/dl14.9 ± 1.612.1 ± 1.812.0 ± 1.712.3 ± 1.80.77
Cholesterol, mg/dl201.3 ± 32.5187.1 ± 43.4182.5 ± 30.1189.6 ± 41.30.81
Triglycerides, mg/dl97.5 ± 26.7156.3 ± 71.6151.8 ± 74.3159.4 ± 71.10.11
C-reactive protein, mg/L0.35 (0.09-0.54)7.2 (1.5-42.4)9.2 (1.8-45.1)6.6 (1.5-31.6)0.01
Fibrinogen, mg/dl255.7 ± 58.5339.5 ± 98.8343.2 ± 95.2321.1 ± 100.00.04
Uric acid, mg/dl5.04 ± 0.686.74 ± 1.886.59 ± 1.926.82 ± 1.870.47
Proteinuria, mg/24 h/1.73 m270.7 (10.3-91.8)450.6 (30.4-1150.0)520.8 (50.1-1230.2)393.1 (30.4-985.4)0.009
Serum NGAL, ng/ml35.4 (18.9-46.5)515.4 (58.9-1405.5)906.8 (265.8-1460.0)420.3 (62.0-1118.5)0.002
Urinary NGAL, ng/ml6.6 (2.1-9.6)195.6 (4.1-801.6)352.4 (6.8-823.1)125.6 (4.1-560.3)0.005